Prostate PDT dosimetry

Photodiagnosis and Photodynamic Therapy

Volumn 3, Issue 4, 2006, Pages 234-246

  Zhu, Timothy C ^a   Finlay, Jarod C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cimmino feasibility algorithm; Combinatorial search; In vivo; Light fluence rate; Optical properties; Optimization; Photosensitizer concentration; Prostate PDT dosimetry

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; BENZOPORPHYRIN DERIVATIVE; HEMATOPORPHYRIN DERIVATIVE; LUTETIUM TEXAPHYRIN; MESOTETRAHYDROXYPHENYLCHLORIN; PALLADIUM BACTERIOPHEOPHORBIDE; PHOTOFRIN; PHOTOSENSITIZING AGENT; SILICON PTHALOCYANINE 4; TALAPORFIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; BLEACHING; BODY WEIGHT; CANCER; CLINICAL TRIAL; DOSIMETRY; FLUORESCENCE; HUMAN; IMPOTENCE; IN VIVO STUDY; INCONTINENCE; LIGHT; LIGHT SCATTERING; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTODYNAMICS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; QUANTITATIVE ANALYSIS; REVIEW; SPECTRUM; TISSUE; TISSUE OXYGENATION;

EID: 33846030790     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2006.08.002     Document Type: Review

References (103)

1. Jemal A., Seigel R., Ward E., et al. Cancer Statistics, 2006. CA-A Cancer J Clin 56 (2006) 106-130
2. Catalona W.J. Screening for early detection. Lancet 347 (1996) 883-884
3. Dougherty T.J., Gomer D.J., Henderson B.W., et al. Photodynamic Therapy. J Natl Cancer Inst 90 (1998) 889-905
4. Ornstein D.K.O., Herschman J.D., and Andriole G.L. Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 25 (1998) 591-601
5. Nathan T.R., Whitelaw D.E., Chang S.C., et al. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a Phase I study. J Urol 168 (2002) 1427-1432
6. Zaak D., Sroka R., Hoppner M., et al. Photodynamic therapy by means of 5-ALA induced PPIX in human prostate-preliminary results. Med Laser Appl 18 (2003) 91-95
7. Stripp D.C.H., Mick R., Zhu T.C., et al. Phase I trial of Motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. Proc SPIE 5315 (2004) 88-99
8. Verigos K., Stripp D.C.H., Mick R., et al. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol 25 1-2 (2006) 373-388
9. Weersink R.A., Bogaards A., Gertner M., et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B 79 3 (2005) 211-222
10. Weersink R.A., Forbes J., Bisland S., et al. Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol 81 1 (2005) 106-113
11. Pinthus J.H., Bogaards A., Weersink R., Wilson B.C., and Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. J Urol 175 4 (2006) 1201-1207
12. Arnfield M.R., Chapman J.D., Tulip J., Fenning M.C., and McPhee M.S. Optical properties of experimental prostate tumors in vivo. Photochem Photobiol 57 2 (1993) 306-311
13. Chen Q., Wilson B.C., Shetty S.D., Patterson M.S., Cerny J.C., and Hetzel F.W. Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. Radiat Res 147 1 (1997) 86-91
14. Lee L.K., Whitehurst C., Chen Q., Pantelides M.L., Hetzel F.W., and Moore J.V. Interstitial photodynamic therapy in the canine prostate. Br J Urol 80 6 (1997) 898-902
15. Selman S.H., and Keck R.W. The effect of tranurethral light on the canine prostate after sensitization with the photosensitizer tin (II) etiopurpurin dichloride: a pilot study. J Urol 152 (1994) 2129-2132
16. Selman S.H., Keck R.W., and Hampton J.A. Transperineal photodynamic ablation of the canine prostate. J Urol 156 (1996) 258-260
17. Selman S.H., Albrecht D., Keck R.W., Brennan P., and Kondo S. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate. J Urol 165 (2001) 1795-1801
18. Hsi A., Kapatkin A.S., Strandberg J., et al. Photodynamic therapy in the canine prostate using Motexafin lutetium. Clin Cancer Res 7 (2001) 651-660
19. Chang S.C., Buonaccorsi G., MacRobert A., and Brown S.G. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced photoporphyrin IX. Prostate 32 (1997) 89-98
20. Chang S.C., Buonaccorsi G., MacRobert A., and Bown S.G. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin. Int J Cancer 67 (1996) 555-562
21. Dimofte A., Finlay J.C., and Zhu T.C. A method for determination of the absorption and scattering properties interstitially in turbid media. Phys Med Biol 50 (2005) 2291-2311
22. Zhu T.C., Dimofte A., Finlay J.C., et al. Optical properties of human prostate at 732 nm measured in vivo during Motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 81 (2005) 96-105
23. Finlay J.C., Zhu T.C., Dimofte A., et al. In vivo determination of the absorption and scattering spectra of the human prostate during photodynamic therapy. Proc SPIE 5315 (2004) 132-142
24. Wang H.W., Zhu T.C., Putt M.E., et al. In-vivo broadband reflectance measurements of light penetration depth, blood oxygenation, hemoglobin concentration, and drug concentration in human tissues before and after photodynamic therapy. J Biomed Opt 10 1-13 (2005)
25. Finlay J.C., Zhu T.C., Dimofte A., et al. In vivo measurement of fluorescence emission in the human prostate during photodynamic therapy. Proc SPIE 5689 (2005) 299-310
26. Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Busch TM, Hahn SM. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 2006, submitted for publication.
27. Pass H.I. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 85 6 (1993) 443-456
28. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B 39 1 (1997) 1-18
29. Foote C.S. Photosenstizied oxidations and the role of singlet oxygen. Acc Chem Res 1 (1967) 104-110
30. Niedre M., Patterson M.S., and Wilson B.C. Direct near-infrared luminescence detection of singlet oxygen generated by photodynamic therapy in cells in vitro and tissues in vivo. Photochem Photobiol 75 4 (2002) 382-391
31. Niedre M.J., Patterson M.S., Giles A., and Wilson B.C. Imaging of photodynamically generated singlet oxygen luminescence in vivo. Photochem Photobiol 81 4 (2005) 941-943
32. Mang T.S., Dougherty T.J., Potter W.R., Boyle D.G., Somer S., and Moan J. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol 45 (1987) 501-506
33. Jacques S.L., Joseph R., and Gofstein G. How photobleaching effects dosimetery and fluorescence monitoring of PDT in turbid media. Proc SPIE 1881 (1993) 168-179
34. Wilson B.C., Patterson M.S., and Lilge L. Implicit and explicit dosimetry in photodynamic therapy: a new paradigm. Lasers Med Sci 12 (1997) 182-199
35. Georgekoudi I., and Foster T.H. Singlet oxygen-versus nonsinglet oxygen-mediated mechanisms of sensitizer photobleaching and their effects on photodynamic dosimetry. Photochem Photobiol 67 (1998) 612-625
36. Georgakoudi I., Nichols M.G., and Foster T.H. The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol 65 (1997) 135-144
37. Patterson M.S., Wilson B.C., and Graff R. In vivo tests of the concept of photodynamic threshold dose in normal rat liver photosensitized by aluminum chlorosulphonated phthalocyanine. Photochem Photobiol 51 (1990) 343-349
38. Hetzel F.W., Brahmavar S.M., Chen Q., Jacques S.L., Patterson M.S., Wilson B.C., and Zhu T.C. Photodynamic Therapy Dosimetry, AAPM Report No. 88 (2005), Med Phys Publishing, Madison, WI
39. Finlay J.C., Mitra S., and Foster T.H. Photobleaching kinetics of Photofrin in vivo and in multicell tumor spheroids indicate multiple simultaneous bleaching mechanisms. Phys Med Biol 49 (2004) 4837-4860
40. Star W.M. Light dosimetry in vivo. Phys Med Biol 42 (1997) 763-787
41. Dimofte A., Zhu T.C., Hahn S.M., and Lustig R.A. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer. Lasers Surg Med 31 5 (2002) 305-312
42. Baas P., Murrer L., Zoetmulder F.A., Stewart F.A., Ris H.B., van Zandwijk N., Peterse J.L., and Rutgers E.J. Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies. Br J Cancer 76 6 (1997) 819-826
43. Solonenko M., Zhu T.C., and Vulcan T.G. Commissioning of the isotropic light dosimetry system for photodynamic therapy. Med Phys 26 (1999) 1124
44. van Staveren H.J., Marijnissen H.P.A., Aalders M.C., and Star W.M. Construction, quality assurance, and calibration of spherical isotropic fibre optic light diffusers. Lasers Med Sci 10 (1995) 137-147
45. Vulcan T.G., Zhu T.C., Rodriguez C.E., et al. Comparison between isotropic and nonisotropic dosimetry systems during intraperitoneal photodynamic therapy. Lasers Surg Med 26 3 (2000) 292-301
46. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother 42 1 (1998) 13-28
47. Momma T., Hamblin M.R., Wu H.C., and Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 58 23 (1998) 5425-5431
48. Chen B., Pogue B.W., Zhou X., et al. Effect of of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 11 2 Part 1 (2005) 720-727
49. Zhu T.C., Li J., Finlay J.C., et al. In-vivo light dosimetry of interstitial PDT of human prostate. Proc SPIE 6139 61390 (2006) L1-L11
50. Li J., Zhu T.C., and Finlay J.C. Study of light fluence rate distribution in photodyanmic therapy using finite-element method. Proc SPIE 6139 61390 (2006) M1-M8
51. Zhu T.C., Hahn S.M., Kapatkin A.S., et al. In-vivo optical properties of normal canine prostate at 732 nm using motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol 77 (2003) 81-88
52. Ishimaru A. Wave propagation and scattering in random media (1997), IEEE Press, New York
53. Wilson B.C., and Patterson M.S. The determination of light fluence distribution in photodynamic therapy. In: Kessel D. (Ed). Photodynamic therapy of neoplastic disease (1990), CRC Press Inc., Boca Raton 129-144
54. Jacques S. Light distributions from point, line and plane sources for photochemical reactions and fluorescence in turbid biological tissues. Photochem Photobiol 67 (1998) 23-32
55. Nakai T., Nishimura G., Yamamoto K., and Tamura M. Expression of optical diffusion coefficient in high-absorption turbid media. Phys Med Biol 42 (1997) 2541-2549
56. Storn R., and Price K. Differential evolution - a simple and efficient heuristic for global optimization over continuous spaces. J Global Optimization 11 (1997) 341-359
57. Zhu T.C., Bjarngard B.E., Xiao Y., and Yang C.J. Modeling the output ratio in air for megavoltage photon beams. Med Phys 28 6 (2001) 925-937
58. Zhu T.C., Finlay J.C., and Hahn S.M. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during Motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B 79 (2005) 231-241
59. Diamond K.R., Patterson M.S., and Farrell T.J. Quantification of fluorophore concentration in tissue-simulating media by fluorescence measurements with a single optical fiber. Appl Opt 42 (2003) 2436-2442
60. Liu H., Boas D.A., Zhang Y., Yodh A.G., and Chance B. Determination of optical properties and blood oxygenation in tissue using continuous near-infrared light. Phys Med Biol 40 (1995) 1983-1993
61. Kienle A., Lilge L., Patterson M.S., Hibst R., Steiner R.A., and Wilson B.C. Spatially resolved absolute diffuse reflectance measurements for noninvasive determination of the optical scattering and absorptions of biological tissue. Appl Opt 35 (1996) 2304-2313
62. Doornbos R.M.P., Lang R., Aalders M.C., Cross F.W., and Sterenborg H.J. The determination of in vivo human tissue optical properties and absolute chromophore concentrations using spatially resolved steady-state diffuse reflectance spectroscopy. Phys Med Biol 44 (1999) 967-981
63. Solonenko M., Cheung R., Busch T.M., et al. In-vivo reflectance measurement of motexafin lutetium uptake, optical properties, and oxygenation of canine large bowels, kidneys, and prostates. Phys Med Biol 47 (2002) 857-873
64. Nichols M.G., and Foster T.H. Oxygen diffusion and reaction kinetics in the photodynamic therapy of multicell tumour spheroids. Phys Med Biol 39 (1994) 2161-2181
65. Tromberg B.J., Orenstein A., Kimel S., et al. In vivo tumor oxygen tension measurements for the evaluation of the efficiency of photodynamic therapy. Photochem Photobiol 52 (1990) 375-385
66. Henderson B.W., Busch T.M., Vaughan L.A., et al. Photofrin photodynamic therapy can significantly deplete or preserve oxygenation in human basal cell carcinomas during treatment, depending on fluence rate. Cancer Res 60 (2000) 525-529
67. Robinson D.J., de Bruijn H.S., van der Veen N., Stringer M.R., Brown S.B., and Star W.M. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem Photobiol 67 (1998) 140-149
68. Robinson D.J., de Bruijn H.S., van der Veen N., Stringer M.R., Brown S.B., and Star W.M. Protoporphyrin IX fluorescence photobleaching during ALA-mediated photodynamic therapy of UVB-induced tumors in hairless mouse skin. Photochem Photobiol 69 (1999) 61-70
69. Finlay J.C., Conover D.L., Hull E.L., and Foster T.H. Porphyrin bleaching and PDT-induced spectral changes are irradiance dependent in ALA-sensitized normal rat skin in vivo. Photochem Photobiol 73 (2001) 54-63
70. Finlay J.C., Mitra S., and Foster T.H. In vivo mTHPC photobleaching in normal rat skin exhibits unique irradiance-dependent features. Photochem Photobiol 75 (2002) 282-288
71. Finlay J.C., and Foster T.H. Hemoglobin oxygen saturations in phantoms and in vivo from measurements of steady state diffuse reflectance at a single, short source-detector separation. Med Phys 31 7 (2004) 1949-1959
72. Altschuler M.D., Zhu T.C., Li J., and Hahn S.M. Optimized interstitial PDT prostate treatment planning with the Cimmino feasibility algorithm. Med Phys 32 12 (2005) 3524-3536
73. Yu G., Durduran T., Zhou C., et al. Noninvasive monitoring of murine tumor blood flow during and after photodynamic therapy provides early assessment of therapeutic efficacy. Clin Cancer Res 11 9 (2005) 3543-3552
74. Wang H.W., Putt M.E., Emanuele M.J., et al. Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome. Cancer Res 64 20 (2004) 7553-7561
75. Yu G., Durduran T., Zhou C., Zhu T.C., Finlay J.C., Busch T.M., Malkowicz S.B., Hahn S.M., and Yodh A.G. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light. Photochem Photobiol (2006) [Epub ahead of print]
76. Chen Q., and Hetzel F.W. Laser dosimetry studies in the prostate. J Clin Laser Med Surg 16 1 (1998) 9-12
77. Chapman J.D., McPhee M.S., Walz N., et al. Nuclear magnetic resonance spectroscopy and sensitizer-adduct measurements of photodynamic therapy-induced ischemia in solid tumors. J Natl Cancer Inst 83 22 (1991) 1650-1659
78. Lapointe D., Brasseur N., Cadorette J., et al. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice. J Nucl Med 40 5 (1999) 876-882
79. Igbaseimokumo U. Quantification of in vivo Photofrin uptake by human pituitary adenoma tissue. J Neurosurg 101 2 (2004) 272-277
80. Marks P.V., Belchetz P.E., Saxena A., et al. Effect of photodynamic therapy on recurrent pituitary adenomas: clinical phase I/II trial-an early report. Br J Neurosurg 14 4 (2000) 317-325
81. Wiedmann M., Berr F., Schiefke I., et al. Photodynamic therapy in patients with non-resectable hilar cholangiocarcinoma: 5-year follow-up of a prospective phase II study. Gastrointest Endosc 60 1 (2004) 68-75
82. Wiedmann M., Caca K., Berr F., et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 97 11 (2003) 2783-2790
83. Cuenca R.E., Allison R.R., Sibata C., and Downie G.H. Breast cancer with chest wall progression: treatment with photodynamic therapy. Ann Surg Oncol 11 3 (2004) 322-327
84. Touma D., Yaar M., Whitehead S., Konnikov N., and Gilchrest B.A. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 140 1 (2004) 33-40
85. Ericson M.B., Sandberg C., Stenquist B., et al. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome. Br J Dermatol 151 6 (2004) 1204-1212
86. Kelty C.J., Ackroyd R., Brown N.J., Brown S.B., and Reed M.W. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc 18 3 (2004) 452-458
87. Hage M., Siersema P.D., van Dekken H., et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut 53 6 (2004) 785-790
88. Hage M., Siersema P.D., Vissers K.J., et al. Molecular evaluation of ablative therapy of Barrett's oesophagus. J Pathol 205 1 (2005) 57-64
89. Cappugi P., Mavilia L., Campolmi P., Reali E.F., Mori M., and Rossi R. New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid. J Chemother 16 5 (2004) 491-493
90. Loning M., Diddens H., Kupker W., Diedrich K., and Huttmann G. Laparoscopic fluorescence detection of ovarian carcinoma metastases using 5-aminolevulinic acid-induced protoporphyrin IX. Cancer 100 8 (2004) 1650-1656
91. Frei K.A., Bonel H.M., Frick H., Walt H., and Steiner R.A. Photodynamic detection of diseased axillary sentinel lymph node after oral application of aminolevulinic acid in patients with breast cancer. Br J Cancer 90 4 (2004) 805-809
92. Webber J., and Fromm D. Photodynamic therapy for carcinoma in situ of the anus. Arch Surg 139 3 (2004) 259-261
93. Dragieva G., Hafner J., Dummer R., et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 77 1 (2004) 115-121
94. Dragieva G., Prinz B.M., Hafner J., et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 151 1 (2004) 196-200
95. Rhodes L.E., de Rie M., Enstrom Y., et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 140 1 (2004) 17-23
96. Lui H., Hobbs L., Tope W.D., et al. Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. Arch Dermatol 140 1 (2004) 26-32
97. Azab M., Boyer D.S., Bressler N.M., et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 123 4 (2005) 448-457
98. Hopper C., Kubler A., Lewis H., Tan I.B., and Putnam G. mTHPC-mediated photodynamic therapy for early oral squamous cell carcinoma. Int J Cancer 111 1 (2004) 138-146
99. Lou P.J., Jager H.R., Jones L., Theodossy T., Bown S.G., and Hopper C. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 91 3 (2004) 441-446
100. Shikowitz M.J., Abramson A.L., Steinberg B.M., et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 131 2 (2005) 99-105
101. Chou T.M., Woodburn K.W., Cheong W.F., et al. Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv 2002 3 (2002) 387-394
102. Kereiakes D.J., Szyniszewski A.M., Wahr D., et al. Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: procedural and long-term results. Circulation 108 11 (2003) 1310-1315
103. Lustig R.A., Vogl T.J., Fromm D., et al. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer 98 8 (2003) 1767-1771